Richard Wolfram is an independent U.S. lawyer based in New York City. His practice, launched in 2005, focuses on antitrust counseling and litigation on behalf of corporations, professional organizations and public advocacy entities.
Drawing on his 17 years of experience in antitrust and more than 26 years in commercial litigation, Mr. Wolfram focuses on helping each client achieve its objectives through effective, cost-efficient counseling and/or litigation.
The constructive use of antitrust to achieve these ends often requires 'problem solving' -- taking apart a client's concrete issues, identifying the antitrust component and using this legal tool to the client's advantage, whether as a plaintiff, defendant, amicus (friend of the court) or interested observer.
Technology and business practices continue to undergo rapid transformation. To address today's economic and commercial realities, the effective advocate can use the law creatively, when necessary, to persuade courts and other enforcers to embrace somewhat novel applications of established principles, provided he or she respects the fundamentals and thoroughly marshals the supporting facts.
Mr. Wolfram teams up with other antitrust lawyers, as necessary, and is also called upon by firms seeking antitrust expertise for their clients. Responsiveness and depth of experience and expertise are highly valued by clients, across a range of antitrust issues, and a lean practice model with flexibility for collaboration helps address these needs.
-- These are some of the key components of Mr. Wolfram's antitrust 'toolbox'.
Antitrust addresses both single-firm and joint conduct. Across these categories, Mr Wolfram advises and litigates on:
Antitrust compliance review in these areas is also a key component of his counseling.
Mr. Wolfram has published widely on a number of antitrust topics in U.S. and foreign publications since 1995 and has guest-lectured and spoken at conferences on antitrust. The range and depth of his writing and speaking are an important facet of his ability to deliver results for his clients.
He has practiced predominantly in antitrust since 1995, including nine years at Clifford Chance/Rogers & Wells in New York City. From 1985 to 1995, Mr. Wolfram worked as an associate in commercial litigation at several large and medium-sized international firms in New York.
More information about Mr. Wolfram's practice, including representative matters, related experience and educational background, a bibliography and contact information, is available below.
April 5, 2013. Public Comment to DOJ and FTC on Patent Assertion Entities:
March 27, 2012. Panelist, "Three Faces of Frand: The Evolving Understanding of Standards Essential Patents," ABA webinar, Science & Technology and Intellectual Property Sections:
Jan. 24, 2012. Connecticut AG Announces Latest Settlement with DRAM Manufacturers - (RW press comment):
Jan. 17, 2012. On the Radar: Massive Credit Card Interchange Fee Multidistrict Litigation - (RW press comment):
Nov. 17, 2011. Jury Rejects $4B RDRAM Antitrust Suit by Rambus - (RW press comment):
April 28, 2011. IOM Urges Reform of Standard Setting in Clinical Practice Guidelines:
Jan. 6, 2011. Article on 'Most Favored Nations' Clauses:
Nov. 15, 2010. Litigation -- IP/Antitrust:
Oct. 13, 2010. ABA teleseminar:
July 13, 2010. Litigation -- Monopolization, Anticompetitive Agreements:
Aug. 2010. Co-author, article on application of antitrust standard setting principles to clinical practice guidelines:
May, June, 2010. American Needle v. NFL (S.Ct.) and Deutscher Tennis Bund v. ATP Tour Inc. (3rd Circuit):
January 6, 2010. Nokia v. Apple -- Spotlight on ETSI/FRAND reciprocity provision:
Oct. 23, 2009. Antitrust developments in resale price maintenance:
Oct. 14-15, 2009. Meetings with FTC and DOJ on standards and open source:
July 30, 2009. Unprecedented hearing by reconstituted guidelines panel on Lyme disease -- pursuant to Connecticut Attorney General's 18-month antitrust investigation and May 2008 settlement regarding the development of clinical guidelines on Lyme disease by the Infectious Diseases Society of America (IDSA) -- followed by issuance of final report by panel in spring 2010:
July 16,2009. Google/antitrust:
July 15, 2009. Article on Standard setting/Rambus:
June 2, 2009. Effects of GM bankruptcy on viability of Saab:
Feb. 23, 2009. Standard Setting - Rambus:
Copyright 2009 Richard Wolfram, Esq. All rights reserved.